Nextrast, Inc. is a biotechnology company developing novel contrasting agents for taking medical images of the bowel and vasculature. Normal CT scan contrasting agents provide ambiguous images of the bowel. Utilizing technology developed by Nextrast Inc founders while they were involved with University of California San Francisco, Nextrast is developing a silicon-based, orally-adminstered contrasting agent which --- when used in conjunction with traditional contrast agents -- delivers sharp and unambiguous images of the bowel and vasculature in a single CT pass. This reduces potential radiation exposure as well as equipping doctors with a vital tool for when bowel and vasculature imaging is needed.
